**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Karan Shahi, Libin Cardiovascular Institute (University of Calgary), Calgary Alberta (Canada)

**Main Body of the Abstract**
Background:
Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an infiltrative process with poor prognosis when left untreated. Despite the approval of tafamidis therapy, significant knowledge gaps exist regarding its use. This project determined baseline predictors of all-cause and cardiovascular mortality and hospitalization, as well as the associations of these predictors to therapy in a clinical cohort from an ATTR-CM referral center. It was hypothesized that select baseline variables will be associated with mortality and the need for hospitalization after the initiation of targeted ATTR-CM therapy.
Methods:
Multivariable modeling was performed with backward stepwise selection to obtain predictors for each event, considering only those variables that demonstrated statistical significance in the univariable analysis. Cox proportional hazard or competing risk regression were used, with ATTR-CM therapy modeled as a time-varying covariate.
Results:
A total of 145 patients with ATTR-CM were identified from 2011 to 2021. Eighty (55%) patients were treated with tafamidis. After 2.9±1.8 years of follow-up, there were a total of 58 death events, of which 49 deaths were cardiovascular-related. The likelihood of experiencing all-cause or cardiovascular mortality increased with advancing age, greater frailty, and impaired renal and right ventricular function (all p<0.05, Table 1), however no interactions with treatment were identified. Kidney function significantly interacted with treatment for cardiovascular hospitalization, such that lower eGFR at baseline was associated with less benefit from therapy (HR [95% CI], 0.93 [0.87-0.99], p<0.05).
Conclusion:
Important baseline criteria associated with ATTR-CM disease prognosis and major adverse events included age, renal function, frailty, and right ventricular function.



Baseline predictors of major adverse events for transthyretin amyloidosis cardiomyopathy patients treated and untreated with disease-modifying therapy PC57 (#216)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.